Compare BioNano Genomics Inc (BNGO) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Beyond Meat Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Beyond Meat Inc trades at $0.4 (market cap $215.41M). The key difference: Beyond Meat Inc is far larger — about 15.8× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | BYND | |
|---|---|---|
Market Cap | $13.66M | $215.41M |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $3.62 |
52-Week Low | $1.06 | $0.42 |
Enterprise Value | $16.26M | $455.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
BYND trades at $0.40, down 22.6% amid a 30:1 reverse stock split announced August 14, 2026. Despite beating Q2 2026 EPS estimates, revenue has declined from $419M in 2022 to $275M in 2025. The stock shows bearish technical signals with oversold RSI readings. Analyst consensus is heavily bearish with 57% sell ratings, reflecting concerns over cash burn and market positioning.
The outlook remains challenging with declining revenues and negative operating cash flow. Investment opportunity exists if turnaround efforts succeed in international markets, but risks include persistent cash burn, competitive pressures, and execution uncertainty. The reverse split addresses listing requirements but doesn't resolve fundamental business challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
